scholarly journals IRON METABOLISM

Blood ◽  
1950 ◽  
Vol 5 (11) ◽  
pp. 983-1008 ◽  
Author(s):  
CLEMENT A. FINCH ◽  
MARK HEGSTED ◽  
THOMAS D. KINNEY ◽  
E. D. THOMAS ◽  
CHARLES E. RATH ◽  
...  

Abstract On the basis of experimental and clinical observations and a review of the literature, a concept of the behavior of storage iron in relation to body iron metabolism has been formulated. Storage iron is defined as tissue iron which is available for hemoglobin synthesis when the need arises. This iron is stored intracellularly in protein complex as ferritin and hemosiderin. It would appear that wherever the cell is functionally intact, such iron is available for general body needs. Iron is transported by a globulin of the serum to and from the various tissues of the body to satisfy their metabolism. Surplus iron carried by this iron-binding protein is deposited chiefly in the liver. Storage iron may be increased in two ways. The first mechanism results from the inability of the body to excrete significant amounts of iron. Because of this, any decrease in circulating red cell iron (any anemia other than blood loss or iron deficiency anemia) is accompanied by a shift of iron to the tissue compartment. The total amount of body iron remains constant and is merely redistributed. This is to be contrasted with the absolute increase in body iron and enlarged iron stores which follow excessive iron absorption or parenteral iron administration. Enlarged iron stores in either instance may be evaluated by examination of sternal marrow or determination of the serum iron and saturation of the iron binding protein In states of iron excess, differences in initial distribution are observed, depending on the route of administration and type of iron compound employed. Iron absorbed from the gastro-intestinal tract and soluble iron salts injected in small amounts are transported by the iron-binding protein of the serum and stored predominantly in the liver. Colloidal iron given intravenously is taken up by the reticulo-endothelial tissue. Erythrocytes appear to localize in greatest concentration in the spleen, while greater amounts of hemoglobin iron are found in the renal parenchyma. These latter differences in distribution reflect the capacity of various body tissues to assimilate different iron compounds, which while present in the plasma are not carried by the iron-binding protein. Over a period of time an internal redistribution of iron from these various sites occurs through the serum iron compartment. The liver becomes progressively loaded with iron. When the capacity of the liver to store iron is exceeded, the serum iron increases and secondary tissue receptors begin to fill with iron. That iron in large amounts is toxic to tissues is suggested by the occurrence of fibrosis in the organs most heavily laden with iron. This sequence of events, whether following excessive iron absorption or parenteral iron administration is believed to be responsible for the clinical and pathologic picture of hemochromatosis.

Blood ◽  
1963 ◽  
Vol 21 (1) ◽  
pp. 33-38 ◽  
Author(s):  
SIMEON POLLACK ◽  
STANLEY P. BALCERZAK ◽  
WILLIAM H. CROSBY

Abstract A loop isolated in situ has been used to study iron absorption in the dog. An infusion of iron salt into the artery supplying the isolated loop fails to stop the absorption of iron from the lumen of the gut. Iron absorption appears to be independent of the relative saturation of iron-binding protein.


PEDIATRICS ◽  
1966 ◽  
Vol 37 (2) ◽  
pp. 383-383
Author(s):  
JOHN T. MCENERY

In the September issue of Pediatrics (36: 322, 1965) Dr. Charles Whitten reported his experiences in the use of Desferrioxamine-B, an iron specific chelating agent, in children with acute iron poisoning. He stated that the iron-desferrioxamine complex was toxic to dogs. Since the complexing of desferrioxamine and ferrous salts is a logarithmic progression after binding 50% of the serum iron in excess of the iron-binding protein it is most likely that the dogs died of the effects of iron poisoning.


1950 ◽  
Vol 92 (4) ◽  
pp. 367-373 ◽  
Author(s):  
Charles L. Yuile ◽  
John W. Hayden ◽  
James A. Bush ◽  
Henry Tesluk ◽  
Wellington B. Stewart

The absorption of a test amount of radioactive iron during artificial saturation of the plasma iron-binding protein, by the repeated intravenous injection of small amounts of iron, was measured in three normal and four anemic dogs. The procedure had no detectable influence on the iron absorption of the normal dogs nor on that of two of the anemic dogs. Two other anemic dogs showed some suppression of iron absorption, though the amount absorbed was still in excess of that absorbed by a normal dog. The reasons for this suppression are not clear from these experiments. Artificially raising the plasma iron to normal levels in one anemic dog did not influence the absorption of iron from the gastrointestinal tract nor was a delayed effect noted after the plasma iron had fallen to base line levels after 5 hours of artificial saturation. It appears that the plasma iron-binding protein and its relative saturation play little role per se in the control of iron absorption in dogs.


1959 ◽  
Vol 38 (1 Pt 1-2) ◽  
pp. 161-185 ◽  
Author(s):  
James H. Jandl ◽  
John K. Inman ◽  
Richard L. Simmons ◽  
David W. Allen

Blood ◽  
1962 ◽  
Vol 20 (2) ◽  
pp. 173-185 ◽  
Author(s):  
MARCEL E. CONRAD ◽  
WILLIAM H. CROSBY ◽  
N. R. Benjamin

Abstract 1. The sequence of characteristic changes of progressive iron deficiency was demonstrated by serial bleeding of normal volunteers and polycythemic patients. 2. After bloodletting, changes occurred in peripheral blood in the following order: a) fall in hemoglobin concentration; b) decreased plasma iron; c) reticulocytosis, increased MCV and MCH; d) diminution of MCV and MCH, increased total iron-binding protein; and e) decreased MCHC. 3. Characteristic changes of iron deficiency returned to prephlebotomy levels in the following sequence: a) hemoglobin concentration; b) cellular indices; c) serum iron; d) serum iron binding protein; and e) bone marrow hemosiderin, and finally the increased gastrointestinal absorption of iron reverted to normal. 4. Accelerated production of red cells continued in polycythemic patients despite the induction of moderate iron deficiency. Quality was sacrificed for quantity, and thereby a more profound microcytosis occurred than in normal subjects with a similar degree of iron deficiency.


GYNECOLOGY ◽  
2018 ◽  
Vol 20 (2) ◽  
pp. 9-13
Author(s):  
A R Khachaturian ◽  
E V Misharina ◽  
M I Yarmolinskaya

Androgen-dependent dermopathy, as well as premenstrual syndrome of varying severity in young women, can cause emotional depression, difficulties in social adaptation and even depressive disorders. The aim of the study was to study the safety and efficacy of using a combined oral contraceptive (COC) Dimia® containing 20 μg ethinyl estradiol and 3 mg drospirenone in young women, as well as its therapeutic effects in androgen-dependent dermopathy. Materials and methods. The study included 57 young women aged 23.1±2.2 years with signs of androgen-dependent dermopathy. The evaluation of the change in the character of menstrual bleeding, the anthropometric parameters (body weight, waist circumference and hips), the therapeutic effect of the drug on the symptoms of androgen-dependent dermopathy, as well as the dynamics of arterial pressure, hemoglobin level, serum iron have been studied. The psycho-emotional state was assessed using the SAN questionnaire (well-being-activity-mood). Results. During 6 months of observation, there was no significant change in the body mass index, waist circumference, and hips, and the drug did not affect the blood pressure numbers. Against the background of taking the drug, there was an increase in the parameters of iron metabolism (hemoglobin content, serum iron). After 3 months of taking the contraceptive with drospirenone, the number of patients with a complaint about the abundance of menstruation decreased more than twofold (from 22.8 to 10.5%), and after 6 months of taking the drug no patient noted the profuse nature of menstruation. Before the start of taking COC with drospirenone, 57.9% of women reported painful menstrual bleeding. Against the background of taking the contraceptive within 3 months, this complaint was stopped in all patients. Sufficient efficacy of treatment of androgen dependent dermopathy in young women with the help of a microdosed drospirenone-containing combined oral contraceptive is estimated from the dermatological acne index. The analysis of the SAN questionnaire made it possible to reveal the improvement in the psychoemotional state of patients on the background of taking the drug. The conclusion. The results obtained proved the effectiveness and safety of the microclinized COC Dimia®. The drug has no significant effect on body weight, blood pressure, provides reliable control of the cycle and a decrease in menstrual bleeding, which results in stabilization of iron metabolism in the body. Dimia® is effective in the treatment of androgen-dependent dermopathy and can be recommended to young women for starting contraception.


Sign in / Sign up

Export Citation Format

Share Document